MUNICH — A new and highly selective inhibitor of phosphatidylinositol-3-kinase (PI3K) has shown benefit in advancedbreast cancerand may succeed where two previous drugs aimed at the same target failed. Fabrice André, MD, PhD The new investigational drug alpelisib (Novartis) is an alpha-specific...
A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation Xin Peng Xin Huang Dexin Kong Molecular Cancer(2024) Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models ...
对于既往经CDK4/6抑制剂治疗后伴PIC3CA突变的HR阳性HER-2阴性晚期乳腺癌患者,BYLieve研究首次证实,CDK4/6抑制剂治疗后,接受Alpelisib联合芳香化酶抑制剂(aromatase inhibitor, AI)或氟维司群均可获益。同时,既往CDK4/6抑制剂治疗持续时...
Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer[J] . Elena Geuna,Andrea Milani,Rossella Martinello,Caterina Aversa,Giorgio Valabrega,Maurizio Scaltriti,Filippo Montemurro.Expert Opinion on Investigational Drugs . 2015 (3)...
2.Ippen Franziska M,Alvarez-Breckenridge Christopher A,Kuter Benjamin M et al. The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in -Mutant Breast Cancer Brain Metastases.[J] .Clin. Cancer Res., 2019, undefined: undefined. ...
[8]Edgar K, Hong R, Song K, et al. Abstract P3-11-23: GDC-0077 is a selective PI3K alpha inhibitor with robust efficacy in PIK3CA mutant hormone-positive breast cancer models. Cancer Research, 2020, 80(4_Suppl...
1. Christine Fritsch, etc. Characterization of the Novel and Specific PI3Ka Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials.Small Molecule Therapeutics, 2014, 13.2. Setiawan V. W., etc. Breast cancer risk factors defined by estrogen and progesterone ...
Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014;13(2):140-156. Edgar K, Hong R, Song K, et al. GDC-0077 is a selective PI3K alpha inhibitor with robust efficacy in PIK3CA mutant hormone-positive breast cancer models. Cancer Res....
8. 2020 ASCO abstract 1006: Alpelisib + Fulvestrant in Patients With PIK3CA-Mutated Hormone-Receptor Positive (HR+), Human Epidermal Growth Factor Receptor-2-Negative (HER2–) Advanced Breast Cancer (ABC) Previously Treated With Cyclin-Dependent Kinase 4/6 Inhibitor (CDKi) + Aromatase Inhibitor (...
et al. Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-...